Helicobacter pylori (H. pylori) is a bacterium found in the stomach and/or duodenum that has been linked to several health conditions, primarily gastric ulcers. The presence of H. pylori is the strongest and most independent risk factor for gastric cancer. Some experts suggest that H. pylori may be as carcinogenic to the stomach as cigarette smoking is to the lungs.
In industrialized countries H. pylori is present in about 20% of people below the age of 40 and in 50% of those above the age of 60. In developing countries, most adults are infected. Most people infected do not develop symptoms related to the infection, however, H. pylori causes various forms of gastritis (chronic active, chronic persistent, and atrophic) in adults and children. Correct diagnosis is important in order to prescribe proper therapy.
The BreathID® System is a revolutionary platform capable of assessing a range of gastrointestinal disorders via molecular analysis of the patient's exhaled breath. The system is the only breath-testing technology that provides continuous, automatic and real-time patient monitoring and data analysis. BreathID® uses a clinically proven, sophisticated laser-like light source to pinpoint real-time changes in 13C/12C isotope ratios at an accuracy level of single parts per million. It is a paradigm change in the way liver and GI disorders are assessed and managed. Covered by more than 60 patents and patent applications worldwide, the BreathID® system is one of the most versatile and advanced diagnostic platforms for hepatologists and gastroenterologists in today`s medical environment.
The BreathID® Helicobacter pylori test has a number of benefits compared to existing urea breath tests, including the following:
- The test has a sensitivity and specificity of more than 99% correlated with a biopsy.
- Results are provided immediately so there is no need to send the testing kits to the laboratory for analysis. Treatment decisions can be made on the spot.
- Test duration is extremely short. In fact, approximately 96% of patients complete it within 10 minutes.
- BreathID® enables two testing modes, allowing maximum flexibility.